Priming the body to receive the therapeutic agent to redefine treatment benefit/risk profile

[1]  L. Lévy,et al.  Nano-sized cytochrome P450 3A4 inhibitors to block hepatic metabolism of docetaxel , 2017, International journal of nanomedicine.

[2]  A. Maiocchi,et al.  In vivo tumor targeting and biodistribution evaluation of paramagnetic solid lipid nanoparticles for magnetic resonance imaging. , 2017, Nanomedicine : nanotechnology, biology, and medicine.

[3]  Ian D. McGilvray,et al.  Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[4]  Scott E. McNeil,et al.  Evaluation of nanomedicines: stick to the basics , 2016, Nature Reviews Materials.

[5]  W. Saltzman,et al.  Cellular distribution of injected PLGA-nanoparticles in the liver. , 2016, Nanomedicine : nanotechnology, biology, and medicine.

[6]  D. Mould,et al.  Drug Development of Therapeutic Monoclonal Antibodies , 2016, BioDrugs.

[7]  A. J. Tavares,et al.  Analysis of nanoparticle delivery to tumours , 2016 .

[8]  M. Chetty,et al.  Potential Sources of Inter-Subject Variability in Monoclonal Antibody Pharmacokinetics , 2016, Clinical Pharmacokinetics.

[9]  Paul Polakis,et al.  Antibody Drug Conjugates for Cancer Therapy , 2016, Pharmacological Reviews.

[10]  M. Dolan,et al.  Chemotherapy-induced peripheral neuropathy: Current status and progress. , 2016, Gynecologic oncology.

[11]  Mauro Ferrari,et al.  Safety of Nanoparticles in Medicine. , 2015, Current drug targets.

[12]  R. Ober,et al.  Targeting FcRn for the modulation of antibody dynamics. , 2015, Molecular immunology.

[13]  Mauro Ferrari,et al.  Principles of nanoparticle design for overcoming biological barriers to drug delivery , 2015, Nature Biotechnology.

[14]  W. Zamboni,et al.  Formulation and physiologic factors affecting the pharmacology of carrier-mediated anticancer agents , 2015, Expert opinion on drug metabolism & toxicology.

[15]  S. Baboota,et al.  Immunosuppressive drug therapy – biopharmaceutical challenges and remedies , 2015, Expert opinion on drug delivery.

[16]  A. Sparreboom,et al.  Inter-patient variability in docetaxel pharmacokinetics: A review. , 2015, Cancer treatment reviews.

[17]  Kevin J. Kauffman,et al.  Cancer nanotherapeutics in clinical trials. , 2015, Cancer treatment and research.

[18]  W. Lencer,et al.  FcRn: The Architect Behind the Immune and Nonimmune Functions of IgG and Albumin , 2015, The Journal of Immunology.

[19]  R. Zhou,et al.  RES blockade: A strategy for boosting efficiency of nanoparticle drug , 2015 .

[20]  Gurvinder Kaur,et al.  PLGA: a unique polymer for drug delivery. , 2015, Therapeutic delivery.

[21]  Liang-Chih Liu,et al.  Safety and efficacy of pegylated liposomal doxorubicin-based adjuvant chemotherapy in patients with stage I-III triple-negative breast cancer. , 2014, Anticancer research.

[22]  Martin G Pomper,et al.  State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[23]  Samir Mitragotri,et al.  Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies , 2014, Nature Reviews Drug Discovery.

[24]  R. Kurzrock,et al.  Toxicity of targeted therapy: Implications for response and impact of genetic polymorphisms. , 2014, Cancer treatment reviews.

[25]  Huile Gao,et al.  The interaction of nanoparticles with plasma proteins and the consequent influence on nanoparticles behavior , 2014, Expert opinion on drug delivery.

[26]  P. Naidoo,et al.  Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: the case of efavirenz , 2014, European Journal of Clinical Pharmacology.

[27]  Aniruddha Roy,et al.  Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[28]  Michael Reth,et al.  Matching cellular dimensions with molecular sizes , 2013, Nature Immunology.

[29]  Krishnendu Roy,et al.  Intracellular delivery of polymeric nanocarriers: a matter of size, shape, charge, elasticity and surface composition. , 2013, Therapeutic delivery.

[30]  F. Yeh,et al.  Decreased reticuloendothelial system clearance and increased blood half-life and immune cell labeling for nano- and micron-sized superparamagnetic iron-oxide particles upon pre-treatment with Intralipid. , 2013, Biochimica et biophysica acta.

[31]  Gang Zheng,et al.  Engineering multifunctional nanoparticles: all-in-one versus one-for-all. , 2013, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[32]  Yoko Yamaguchi,et al.  Pathogenesis of Hand-Foot Syndrome induced by PEG-modified liposomal Doxorubicin , 2013, Human Cell.

[33]  K. Giacomini,et al.  Renal transporters in drug development. , 2013, Annual review of pharmacology and toxicology.

[34]  Y. Gavhane,et al.  Loss of orally administered drugs in GI tract. , 2012, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[35]  Rebekah Drezek,et al.  In vivo biodistribution of nanoparticles. , 2011, Nanomedicine.

[36]  W. Hou,et al.  Facile synthesis of concentrated gold nanoparticles with low size-distribution in water: temperature and pH controls , 2011, Nanoscale research letters.

[37]  Kit S Lam,et al.  The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. , 2011, Biomaterials.

[38]  J. DeSimone,et al.  Drug delivery: Relieving PEGylation. , 2011, Nature chemistry.

[39]  Jos H. Beijnen,et al.  Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies , 2010, Clinical pharmacokinetics.

[40]  P. Grutter,et al.  Effect of mechanical properties of hydrogel nanoparticles on macrophage cell uptake , 2009 .

[41]  Francesca Ungaro,et al.  Controlled drug delivery in tissue engineering. , 2008, Advanced drug delivery reviews.

[42]  Rene Bruno,et al.  Clinical pharmacokinetics of bevacizumab in patients with solid tumors , 2008, Cancer Chemotherapy and Pharmacology.

[43]  Magnus Ingelman-Sundberg,et al.  Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. , 2007, Pharmacology & therapeutics.

[44]  S. Larson,et al.  Improved tumor imaging and therapy via i.v. IgG-mediated time-sequential modulation of neonatal Fc receptor. , 2007, The Journal of clinical investigation.

[45]  E. Wisse,et al.  Species differences in transgene DNA uptake in hepatocytes after adenoviral transfer correlate with the size of endothelial fenestrae , 2007, Gene Therapy.

[46]  M. Ingelman-Sundberg,et al.  Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. , 2007, Pharmacology & therapeutics.

[47]  M. Garnett,et al.  Nanomedicines and nanotoxicology: some physiological principles. , 2006, Occupational medicine.

[48]  John W. Park,et al.  Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. , 2006, Cancer research.

[49]  G. Wilkinson,et al.  Drug metabolism and variability among patients in drug response. , 2005, The New England journal of medicine.

[50]  S. Akilesh,et al.  The MHC class I-like Fc receptor promotes humorally mediated autoimmune disease. , 2004, The Journal of clinical investigation.

[51]  M Heath-Chiozzi,et al.  Clinical application of pharmacogenetics. , 2001, Trends in molecular medicine.

[52]  M J Cupp,et al.  Cytochrome P450: new nomenclature and clinical implications. , 1998, American family physician.

[53]  D. Papahadjopoulos,et al.  Recognition of liposomes by cells: in vitro binding and endocytosis mediated by specific lipid headgroups and surface charge density. , 1992, Biochimica et biophysica acta.

[54]  D. Lasič,et al.  The mechanism of vesicle formation. , 1988, The Biochemical journal.

[55]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[56]  Wang,et al.  Stick to the Basics , 1984 .

[57]  A. Nowotny.  Microdetermination of Phosphorus , 1979 .

[58]  P. S. Chen,et al.  Microdetermination of Phosphorus , 1956 .